OCGN Oct 2024 3.500 call
| Previous Close | 0.4800 |
| Open | 0.2000 |
| Bid | 0.2000 |
| Ask | 0.4500 |
| Strike | 3.50 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.2000 - 0.2800 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 211 |
ZacksIs Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.
GlobeNewswireOcugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada. “I’m very pleased to present OC
- GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p
